Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the Senate passage of comprehensive opioid legislation, the SUPPORT for Patients and Communities Act (H.R. 6).
Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the introduction of the Using Data to Prevent Opioid Diversion Act of 2018 (H.R. 6779) by Rep. Ken Buck (R-Colo.)
The Healthcare Distribution Alliance (HDA) will convene pharmaceutical supply chain industry leaders at its Traceability Seminar, October 17–19 in Washington, D.C. The 2018 seminar will educate attendees about where the pharmaceutical supply chain is in relation to achieving full implementation of the Drug Supply Chain Security Act (DSCSA) in 2023; what to expect in the future as the industry approaches the final deadline; and available resources, tools and guidance on a range of traceability topics.
A new report published by the HDA Research Foundation entitled The Role of Reverse Distribution provides insights into the reverse distribution of pharmaceutical products. The Foundation estimates that this channel accounts for 3.5 to 4 percent of all pharmaceutical sales — more than 120 million product units — and exceeds $13 billion in product value.
Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the Department of Health and Human Services’ (HHS) recent directive to establish a Food and Drug Administration (FDA) work group to examine prescription drug importation policies.
John Parker
(703) 885-0216
Farah Simonett
(703) 885-0269
